Skip to main content
Evidence Snapshot

Orexin/Hypocretin receptor type 1

CHEMBL5113 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:27Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5113
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Orexin/Hypocretin receptor type 1 as ChEMBL target CHEMBL5113, mapped to UniProt O43613. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Orexin/Hypocretin receptor type 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5113
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O43613
Orexin/Hypocretin receptor type 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Orexin/Hypocretin receptor type 1 matters

As of 2026-09-13

Orexin/Hypocretin receptor type 1 is reviewed as Orexin/Hypocretin receptor type 1 (UniProt O43613); Orexin/Hypocretin receptor type 1 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 7 approved drugs, 8128 compounds, and 268 assays, with lead potency reaching pChEMBL 10.2.

Disease context
insomnia

Orexin/Hypocretin receptor type 1 shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include DARIDOREXANT HYDROCHLORIDE, LEMBOREXANT, SB-649868.

Start review with insomnia because it currently carries approved-linked support. Linked drugs include DARIDOREXANT HYDROCHLORIDE, LEMBOREXANT, SB-649868. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 3 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 8128 compounds, and 268 assays for this target. The dominant activity type is IC50. CHEMBL3597953 is the current potency anchor at pChEMBL 10.2.

Use CHEMBL3597953 as the tractability anchor when discussing potency (pChEMBL 10.2).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Orexin/Hypocretin receptor type 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O43613, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why insomnia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

8128
Total Compounds
268
Total Assays
7
Approved Drugs
IC50: 6138.0, KI: 4420.0, EC50: 310.0, KD: 158.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3597953
 10.2 Ki —
No preferred name
CHEMBL5079059
 10.2 EC50 —
No preferred name
CHEMBL5619450
 10.0 IC50 —
No preferred name
CHEMBL3906374
 10.0 IC50 —
No preferred name
CHEMBL1830963
 9.9 Ki —

Approved Drugs

Structure Compound First Approval
DARIDOREXANT
CHEMBL4297590
 2022
LEMBOREXANT
CHEMBL3545367
 2020
SUVOREXANT
CHEMBL1083659
 2014
NALFURAFINE
CHEMBL267495
 2009
NALFURAFINE HYDROCHLORIDE
CHEMBL490665
 2009
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:27Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5113